Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products
- PMID: 20736327
- PMCID: PMC2932769
- DOI: 10.1158/1078-0432.CCR-10-0663
Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products
Abstract
Purpose: Several recent oral oncology drugs were labeled for administration in fasted states despite the fact that food increases their bioavailability. Because this was inconsistent with the principles of oral drug delivery, we hypothesized that there were inconsistencies across therapeutic areas.
Experimental design: Oral agents approved by the U.S. Food and Drug Administration from January 2000 to May 2009 were included in our study. Comparison of the food labeling patterns between oncology and non-oncology drugs was made using Fisher's exact test.
Results: Of the 99 drugs evaluated, 34 showed significant food effects on bioavailability. When food markedly enhanced bioavailability, eight out of nine non-oncology drugs were labeled "fed" to take advantage of the food-drug interaction, whereas all oncology drugs (n = 3) were labeled to be administered in "fasted" states (Fisher's exact test, P = 0.01).
Conclusions: Drug labeling patterns with respect to food-drug interactions observed with oncology drugs are in contradiction with fundamental pharmacologic principles, as exemplified in the labeling of non-oncology drugs. .
Figures


Comment in
-
Food and oral antineoplastics: more than meets the eye.Clin Cancer Res. 2010 Sep 1;16(17):4305-7. doi: 10.1158/1078-0432.CCR-10-1857. Epub 2010 Aug 24. Clin Cancer Res. 2010. PMID: 20736331
Similar articles
-
Food and oral antineoplastics: more than meets the eye.Clin Cancer Res. 2010 Sep 1;16(17):4305-7. doi: 10.1158/1078-0432.CCR-10-1857. Epub 2010 Aug 24. Clin Cancer Res. 2010. PMID: 20736331
-
To Take or Not to Take With Meals? Unraveling Issues Related to Food Effects Labeling for Oral Antineoplastic Drugs.Clin Pharmacol Drug Dev. 2018 Jun;7(5):455-464. doi: 10.1002/cpdd.416. Epub 2017 Dec 2. Clin Pharmacol Drug Dev. 2018. PMID: 29197167
-
Food Effect Studies for Oncology Drug Products.Clin Pharmacol Ther. 2017 May;101(5):606-612. doi: 10.1002/cpt.610. Epub 2017 Mar 20. Clin Pharmacol Ther. 2017. PMID: 28073144 Review.
-
Flushing oral oncology drugs down the toilet.J Clin Oncol. 2011 Oct 20;29(30):3958-9. doi: 10.1200/JCO.2011.37.1617. Epub 2011 Sep 19. J Clin Oncol. 2011. PMID: 21931020 No abstract available.
-
Impact of dosage timing on the bioavailability of oral anticancer medications: Is pre-prandial dosing equivalent to post-prandial dosing.J Oncol Pharm Pract. 2019 Mar;25(2):404-408. doi: 10.1177/1078155217752535. Epub 2018 Jan 17. J Oncol Pharm Pract. 2019. PMID: 29343152 Review.
Cited by
-
Lipid-associated oral delivery: Mechanisms and analysis of oral absorption enhancement.J Control Release. 2016 Oct 28;240:544-560. doi: 10.1016/j.jconrel.2016.07.050. Epub 2016 Aug 9. J Control Release. 2016. PMID: 27520734 Free PMC article. Review.
-
Effects of food and grapefruit juice on single-dose pharmacokinetics of blonanserin in healthy Chinese subjects.Eur J Clin Pharmacol. 2018 Jan;74(1):61-67. doi: 10.1007/s00228-017-2340-1. Epub 2017 Oct 3. Eur J Clin Pharmacol. 2018. PMID: 28975417
-
Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer.J Thorac Oncol. 2011 May;6(5):951-3. doi: 10.1097/JTO.0b013e31820db227. J Thorac Oncol. 2011. PMID: 21623267 Free PMC article. Clinical Trial.
-
Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets.JCO Glob Oncol. 2020 Mar;6:382-386. doi: 10.1200/JGO.19.00341. JCO Glob Oncol. 2020. PMID: 32125899 Free PMC article.
-
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.Leukemia. 2016 Apr;30(4):889-96. doi: 10.1038/leu.2015.265. Epub 2015 Oct 7. Leukemia. 2016. PMID: 26442612 Free PMC article. Clinical Trial.
References
-
- DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol. 1998 Jul;16(7):2557–67. - PubMed
-
- Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002 May 1;94(9):652–61. - PubMed
-
- Singh BN, Malhotra BK. Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet. 2004;43(15):1127–56. - PubMed
-
- Ratain MJ, Cohen EE. The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol. 2007 Aug 10;25(23):3397–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical